Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protein Design Labs Discontinues Daclizumab Development For Colitis; Asthma Is “Top Priority” Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm is discontinuing development for ulcerative colitis in light of a Phase II study that failed to meet the primary efficacy endpoint: remission at week eight. Follow-on Phase II studies in asthma and multiple sclerosis are expected to begin by the first quarter of 2005.

You may also be interested in...



Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal

The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.

Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal

The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.

PDL/Roche Targeting Broad Zenapax Asthma Indication Under Development Deal

Roche signs on to PDL’s plans for daclizumab in development/marketing agreement for “asthma and related respiratory diseases.” PDL hopes initial asthma indication will be broader than that of Genentech/Novartis’ Xolair.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel